Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 11/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920259 | 0.89 | SYK (0.46) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9923406 | 0.86 | ZAP70 (0.41) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920260 | 0.81 | JAK3 (0.41) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920392 | 0.80 | SYK (0.47) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920254 | 0.79 | SYK (0.46) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9923407 | 0.78 | PIK3CG (0.34) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920395 | 0.78 | TAS1R3 (0.34) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920391 | 0.76 | TAS1R3 (0.34) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9920257 | 0.74 | JAK3 (0.53) | SYKZAP70JAK3JAK2JAK1 | |
| SCHEMBL9923291 | 0.70 | JAK3 (0.42) | SYKZAP70JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | SYK 85/4885ZAP70 20/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.